Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02000895 · ClinicalTrials.gov registry record

BLOOM: Biological Legacy of Origin in Mother-Infant Dyads

A clinical trial of Cardiovascular Diseases and Chronic Kidney Diseases, sponsored by University of Miami.

Recruiting
Registry status
300
Enrollment target
1
Study location

NCT02000895: Recruiting study of Cardiovascular Diseases and Chronic Kidney Diseases, sponsored by University of Miami.

NCT02000895 is a study of Cardiovascular Diseases and Chronic Kidney Diseases that is actively recruiting participants, run by University of Miami. The registered enrollment target is 300 participants, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02000895, a study of Cardiovascular Diseases and Chronic Kidney Diseases, is actively recruiting participants, sponsored by University of Miami.

RECRUITING
Registry status
300 participants
Enrollment target
1
Study location

Study Summary

Infants born preterm and of low birth weight are known to be at increased risk for early onset of cardiovascular and renal disease in adult life. This has been related to low nephron mass due to inadequate or early termination of glomerulogenesis in utero and during the perinatal period. Risks for subsequent development of hypertension and kidney disease include proteinuria, excessive weight gain during early life with insulin resistance and supplemental high calorie feedings. The long-term goal is for early diagnosis of those infants who are at risk for future development of hypertension and kidney disease so that the investigators might intervene to potentially avert progression to adult disease. The objective of this clinical trial is to acquire data on the natural history of neonatal kidney function and size in infants born preterm during the first 2 years of life. This will be done through the use of standard serum and urine markers as well as non-invasive ultrasound technology. The central hypothesis of this clinical trial is that a subgroup of patients born preterm and of low birth weight will demonstrate early markers of kidney injury including elevated serum cystatin C, proteinuria and low kidney size. This hypothesis has been formulated on the basis of preliminary data from our group studying this question retrospectively in older children born prematurely who have developed overt kidney disease. The rationale for the proposed research is to develop early serum and demographic markers of pre-clinical kidney disease so that early intervention can occur. The proposed clinical trial is innovative because it will investigate the risk factors for kidney dysfunction at a pre-clinical stage with the idea of gaining more knowledge regarding therapeutic interventions. In addition, the study will assess serum cystatin C as a surrogate test for glomerular filtration rate which could indicate worsening kidney function at an earlier stage than serum creatinine. The pr

Primary Outcome

TKV will be measured by 2-D and 3-D renal ultrasound

Study Locations (1)

Florida

  • University of Miami/ Holtz Children's Hospital - Miami

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2011-07-23
Est. Completion 2029-01-01
University of Miami

721 total trials

What NCT02000895 shows while recruiting

NCT02000895 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 0 interventions.

NCT02000895 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT02000895 about?

NCT02000895 is a clinical study titled "BLOOM: Biological Legacy of Origin in Mother-Infant Dyads". Infants born preterm and of low birth weight are known to be at increased risk for early onset of cardiovascular and renal disease in adult life. This has been related to low nephron mass due to inadequate or early termination of glomerulogenesis in utero and during the perinatal period. Risks for s...

What is the current status of trial NCT02000895?

This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2011-07-23. Estimated completion is 2029-01-01.

What conditions does trial NCT02000895 study?

This clinical trial studies the following conditions: Cardiovascular Diseases, Chronic Kidney Diseases.

Who is sponsoring clinical trial NCT02000895?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02000895 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02000895's enrollment target sits among peer trials

300 122nd of 300 higher than 175 of 300 other Cardiovascular Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02000895, the US trial registry maintained by the National Library of Medicine. NCT02000895 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.